A striking disparity in genetic profiles illuminates why some prostate cancers progress rapidly while others remain dormant for decades. TP53 mutations—found in approximately 50 percent of metastatic castration-resistant prostate cancers but present in only 5 percent of localized tumours—exemplify how specific genetic alterations fundamentally reshape disease biology. This tenfold difference is not incidental; it reflects the molecular underpinnings of treatment resistance and metastatic potential. TP53 encodes a critical tumour suppressor protein, and its loss removes a major barrier to aggressive progression and therapy evasion. Similar patterns emerge with PTEN and BRCA2 defects, reinforcing that aggressiveness correlates with identifiable genetic events rather than random variation. For clinicians, this genetic stratification offers actionable insight: detecting these mutations in diagnostic testing should prompt intensified surveillance and consideration of aggressive treatment protocols. Understanding these molecular drivers transforms prognostic prediction from statistical extrapolation into biology-based precision medicine.
Was this article helpful?
